Aptevo Therapeutics Inc.(APVO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Aptevo Therapeutics Inc. (APVO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. APVO is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $33.6m in revenue and is scored on the micro-cap board instead. Top institutional holders of APVO by reported 13-F value include GSA CAPITAL PARTNERS LLP, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. APVO trades on the Nasdaq exchange and files with the SEC under CIK 1671584. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate APVO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aptevo Therapeutics Inc. directly from SEC EDGAR.

Net Income

$-6.4M

APVO key financials by period

Aptevo Therapeutics Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202210-K$3.1M$8.0M—
FY 202110-K$12.3M$-28.5M-174.1%
FY 202010-K$4.3M$-17.8M—
FY 201910-K$32.4M$-40.4M-126.3%
FY 201810-K$23.1M$-53.7M—
FY 201710-K$14.7M$7.0M—

Institutions holding APVO

Institutional investors reporting a position in Aptevo Therapeutics Inc. on SEC Form 13F.
InstitutionSharesValueReported
GSA CAPITAL PARTNERS LLP21,539$96.0K2026-06-30
VANGUARD CAPITAL MANAGEMENT12,713$56.4K2026-06-30
GEODE CAPITAL MANAGEMENT10,821$48.0K2026-06-30
VANGUARD FIDUCIARY4,142$18.4K2026-06-30
UBS Group AG730$3.2K2026-06-30
OSAIC360$1.6K2026-06-30
SBI Securities , Ltd.109$484.002026-06-30
BARCLAYS PLC31$138.002026-06-30
DANSKE BANK A/S1$4.002026-06-30
SEC EDGAR: CIK 1671584 →
APVO

Aptevo Therapeutics Inc.

APVO
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $33.6M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-6.36M

EPS (Diluted)

Q2 2026
EDGAR

$-5.31

Top Institutional Holders

as of Q2 2026
$224.3K total
GSA CAPITAL PARTNERS LLP
$96.0K+9.7%
VANGUARD CAPITAL MANAGEMENT LLC
$56.4K0.0%
GEODE CAPITAL MANAGEMENT, LLC
$48.0K-18.9%
VANGUARD FIDUCIARY TRUST CO
$18.4K0.0%
UBS Group AG
$3.2K-78.8%
OSAIC HOLDINGS, INC.
$1.6K0.0%
SBI Securities Co., Ltd.
$4840.0%
BARCLAYS PLC
$138New
DANSKE BANK A/S
$40.0%

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…